Novo reported Q1 sales of DKK 96.8 billion ($15.2 billion), with its oral Wegovy pill, launched January 5, generating DKK 2.26 billion in its first quarter, nearly double the DKK 1.16 billion analysts had expected
It even includes an automatic rotation feature that suggests the next injection site based on your preset preferences helping to minimize repetitive use of the same area, which can lead to issues like lipohypertrophy
20 Thus, drugs utilising GIP, GLP-1, or GLP-2 receptor signalling pathways are already in clinical use, which should make potential application within the bone disease arena less complicated ( Figure 3 )
Wegovy (active ingredient: semaglutide) Initial FDA GLP-1 Drugs Approval: 2021 (semaglutide approved in 2017) Side Effect Update Date: November 1, 2024 Medication Description: Taken to help with weight loss
& Ambery, P